Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer [0.03%]
用于原发性骨癌治疗的优化药物递送纳米载体策略的发展
Lindokuhle M Ngema,Samson A Adeyemi,Yahya E Choonara
Lindokuhle M Ngema
Primary bone cancer is a relatively rare malignant tumor that manifests in the bone and affects the normal functioning of the bone tissue. Primary bone cancer can be characterized into three subtypes, which are osteosarcoma, chondrosarcoma,...
PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression [0.03%]
PRDM1通过LGALS9信号驱动前列腺癌进展中TIM3+免疫抑制性巨噬细胞小生境形成
Yangyang Zhang,Ilyar Mamtili,Yonghao Chen et al.
Yangyang Zhang et al.
Background: Prostate cancer (PCa) responds poorly to immunotherapy. We investigated the myeloid checkpoint TIM3 (HAVCR2) to define its lineage localization and regulatory logic in the PCa microenvironment. Methods: We integrated stage-resol...
Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies [0.03%]
组织不可知的实体瘤治疗：一项关于不同组织学类型中疗效、安全性和耐药决定因素的PRISMA符合性Meta分析
Marwa Balaha,Saad A Aldosari,Ahmed A Alamer et al.
Marwa Balaha et al.
Objectives: Tissue-agnostic oncology personalizes treatments based on shared molecular biomarkers, addressing challenges like assay variability, control-arm rigor, and non-proportional hazards. Integrating efficacy, safety, and resistance f...
Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation [0.03%]
基于乳酰化相关基因的三阴性乳腺癌预后及免疫疗效研究及实验验证
Yang Wang,Ying Xie,Yiyi Ye et al.
Yang Wang et al.
Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast malignancy characterized by poor clinical outcomes and limited therapeutic options. The identification of reliable biomarkers for predicting prognosis and im...
EBF1 Deficiency Drives Prostate Cancer Progression by Interfering with the Transcriptional Regulation of ITPR1 [0.03%]
EBF1通过干扰IP3R1的转录调节促进前列腺癌进展
Yuan Guo,Hui Wang,Xiaoyu Zhao et al.
Yuan Guo et al.
Backgrounds: Early B-cell factor 1 (EBF1), originally identified as a critical transcription factor modulating the development and differentiation of B lymphocytes, has recently attracted significant interest owing to its diverse functional...
BCG Induces PD-1 Upregulation on Circulating CD8+ T Cells and IL-6 and IL-8 Secretion In Vitro [0.03%]
结核菌素诱导外周血CD8阳性T细胞PD-L1表达和IL-6、IL-8释放体外研究
Gabriela R Barbosa,Luciana S B Dal Col,Caroline C Bighetto et al.
Gabriela R Barbosa et al.
Backgrounds: Bacillus Calmette-Guérin (BCG) remains the most effective adjuvant therapy for non-muscle-invasive bladder cancer (NMIBC); however, the immunological underpinnings of its efficacy remain incompletely understood. This study aim...
Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers: Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies [0.03%]
自分泌运动因子衍生四肽十四肽作为双作用化疗增敏剂：在血液系统恶性肿瘤中连接细胞竞争机制与临床多药耐药逆转
Changyul Kim,Yu Ju Jung,Da Hee Son et al.
Changyul Kim et al.
Backgrounds: Autocrine motility factor (AMF) represents a paradoxical protein with dual roles in cancer progression and therapy. This study investigated AMF-derived tetradecapeptides as novel chemosensitizing agents to overcome multidrug re...
Mi Rim Kim,Jason Lau,Michele Maffezzoli et al.
Mi Rim Kim et al.
Antibody-drug conjugates (ADCs) are a promising strategy in non-small cell lung cancer (NSCLC), but early-generation drugs were limited by suboptimal target selection, heterogeneous drug-antibody ratios, and linker instability, resulting in...
Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data [0.03%]
根据临床风险的卵巢癌患者使用PARP抑制剂的无进展生存期：基于重构数据的间接比较研究
Lorenzo Gasperoni,Luna Del Bono,Alberto Farolfi et al.
Lorenzo Gasperoni et al.
Background: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are established maintenance treatments in ovarian cancer, but comparative efficacy across genetic profiles and relapse risk categories remains unclear. The aim of this study...
Comparative Study
Oncology research. 2026 Jun 16;34(7):14. DOI:10.32604/or.2026.077700 2026
Immunometabolic Reprogramming in Hepatocellular Carcinoma Mechanisms, Biomarkers, and Therapeutic Implications [0.03%]
肝细胞癌的免疫代谢重组：机制、生物标志物和治疗意义
Guodong Yu,Weiying Ge,Hongliang Yao et al.
Guodong Yu et al.
Hepatocellular carcinoma (HCC) develops in a chronically inflamed and dysregulated liver metabolism, in which tumor progression and resistance to treatment are orchestrated by the changes in cellular metabolism and immune control. Growing e...